SEC coupled with in-line multiple detectors for the characterization of an oncolytic Coxsackievirus

V937 is an oncolytic virus immunotherapy clinical drug candidate consisting of a proprietary formulation of Coxsackievirus A21 (CVA21). V937 specifically binds to and lyses cells with over-expressed ICAM-1 receptors in a range of tumor cell types and is currently in phase I and II clinical trials. I...

Descripción completa

Detalles Bibliográficos
Autores principales: Deng, James Z., Rustandi, Richard R., Swartz, Andrew, Shieh, Yvonne, Baker, Jack B., Vlasak, Josef, Wang, Shiyi, Loughney, John W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Gene & Cell Therapy 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8718657/
https://www.ncbi.nlm.nih.gov/pubmed/35024440
http://dx.doi.org/10.1016/j.omto.2021.12.009

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8718657/
https://www.ncbi.nlm.nih.gov/pubmed/35024440
http://dx.doi.org/10.1016/j.omto.2021.12.009

Ejemplares similares